SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-095526
Filing Date
2024-08-12
Accepted
2024-08-12 17:05:09
Documents
14
Period of Report
2024-08-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K atra-20240810.htm   iXBRL 8-K 55786
2 EX-10.1 atra-ex10_1.htm EX-10.1 127702
3 EX-10.2 atra-ex10_2.htm EX-10.2 139818
4 EX-99.1 atra-ex99_1.htm EX-99.1 277250
  Complete submission text file 0000950170-24-095526.txt   786247

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atra-20240810.xsd EX-101.SCH 26006
16 EXTRACTED XBRL INSTANCE DOCUMENT atra-20240810_htm.xml XML 4892
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 241197820
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)